Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.

about

Modulation of antitumor immunity with histone deacetylase inhibitors.CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival.

P2860

Q49557954-7CE75B67-F4C2-4630-B9F7-599686AA41A5 Q51746346-257D6866-132C-498E-BA28-98AE2AFA0AAB

P2860

Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.

Item

http://www.wikidata.org/entity/Q41279840

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.

@en

type

Item

label

Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.

@en

prefLabel

Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.

@en

P1476

Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.

@en

P2093

Andres Forero

http://www.w3.org/2001/XMLSchema#string

Angelina Londoño

http://www.w3.org/2001/XMLSchema#string

Ashwini Katre

http://www.w3.org/2001/XMLSchema#string

Haller J Smith

http://www.w3.org/2001/XMLSchema#string

J Michael Straughn

http://www.w3.org/2001/XMLSchema#string

Rebecca C Arend

http://www.w3.org/2001/XMLSchema#string

Selene Meza-Perez

http://www.w3.org/2001/XMLSchema#string

Taylor B Turner

http://www.w3.org/2001/XMLSchema#string

Troy D Randall

http://www.w3.org/2001/XMLSchema#string

P2860

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Analyzing real-time PCR data by the comparative C(T) method

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

P304

44159-44170

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.17395

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jacelyn E Peabody

Donald J Buchsbaum

Lyse A Norian

P577

2017-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28498806

http://www.w3.org/2001/XMLSchema#string

P932

5546470

http://www.w3.org/2001/XMLSchema#string

Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.

about

P2860

P2860

Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932